Variant histology: Role in management and prognosis of nonmuscle invasive bladder cancer

Current Opinion in Urology

Volumn 24, Issue 5, 2014, Pages 517-523

  Porten, Sima P ^a   Willis, Daniel ^a   Kamat, Ashish M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

cystectomy; divergent differentiation; high risk urothelial carcinoma; intravesical immunotherapy; variant histology

Indexed keywords

BCG VACCINE;

ANGIOSARCOMA; CANCER PROGNOSIS; CARCINOID; CELL DIFFERENTIATION; CYSTECTOMY; HEMANGIOMA; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; LEIOMYOMA; LYMPHATIC SYSTEM TUMOR; LYMPHOEPITHELIOMA; LYMPHOMA; MALIGNANT FIBROUS HISTIOCYTOMA; MELANOMA; NEUROENDOCRINE TUMOR; NON MUSCLE INVASIVE BLADDER CANCER; OSTEOSARCOMA; PARAGANGLIOMA; PLASMACYTOID DENDRITIC CELL; PLASMACYTOMA; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; RHABDOMYOSARCOMA; SARCOMATOID CARCINOMA; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA; VILLOUS ADENOMA; ADENOCARCINOMA; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; DISEASE MANAGEMENT; DRUG THERAPY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

ADENOCARCINOMA; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; CYSTECTOMY; DISEASE MANAGEMENT; DRUG THERAPY; HUMANS; PROGNOSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84905383901     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0000000000000089     Document Type: Review

References (42)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30.
2. Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on nonmuscleinvasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013; 64:639-653.
3. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49:466-465.
4. Willis DL, Porten SP, Kamat AM. Should histologic variants alter definitive treatment of bladder cancer? Curr Opin Urol 2013; 23:435-443.
5. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. editors. World Health Organization classification of tumours: pathology and genetics of tumours of the urinary system and male genital organs. Lyon, France: IARC Press; 2004. pp. 1-354.
6. Wasco MJ, Daignault S, Zhang Y, et al. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology 2007; 70:69-74.
7. Shah RB, Montgomery JS, Montie JE, Kunju LP. Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital. Urol Oncol 2013; 31:1650-1655.
8. Kamat AM, Gee JR, Dinney CP, et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 2006; 175:881-885.
9. Ghoneim IA, Miocinovic R, Stephenson AJ, et al. Neoadjuvant systemic therapy or early cystectomy? Single-center analysis of outcomes after therapy for patients with clinically localized micropapillary urothelial carcinoma of the bladder. Urology 2011; 77:867-870.
10. Comperat E, Roupret M, Yaxley J, et al. Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. Pathology (Phila) 2010; 42:650-654.
11. Vourganti S, Harbin A, Singer EA, et al. Low Grade Micropapillary Urothelial Carcinoma, Does It Exist? - Analysis of Management and Outcomes from the Surveillance, Epidemiology and End Results (SEER) Database. J Cancer 2013; 4:336-342.
12. Amin A, Epstein JI. Noninvasive micropapillary urothelial carcinoma: a clinicopathologic study of 18 cases. Hum Pathol 2012; 43:2124-2128.
13. Gaya JM, Palou J, Algaba F, et al. The case for conservative management in the treatment of patients with nonmuscle-invasive micropapillary bladder carcinoma without carcinoma in situ. Canad J Urol 2010; 17:5370-5376.
14. Wright JL, Black PC, Brown GA, et al. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol 2007; 178:2302-2306.
15. Shapur NK, Katz R, Pode D, et al. Is radical cystectomy mandatory in every patient with variant histology of bladder cancer. Rare tumors 2011; 3:e22.
16. Ploeg M, Aben KK, Hulsbergen-van de Kaa CA, et al. Clinical epidemiology of nonurothelial bladder cancer: analysis of the Netherlands Cancer Registry. J Urol 2010; 183:915-920.
17. Kamat AM, Dinney CP, Gee JR, et al. Micropapillary bladder cancer: a review of the M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 2007; 110:62-67.
18. Weizer AZ, Wasco MJ, Wang R, et al. Multiple adverse histological features increase the odds of under staging T1 bladder cancer. J Urol 2009; 182:59-65.
19. Kassouf W, Agarwal PK, Grossman HB, et al. Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology 2009; 73:147-152.
20. Domanowska E, Jozwicki W, Domaniewski J, et al. Muscle-invasive urothelial cell carcinoma of the human bladder: multidirectional differentiation and ability to metastasize. Hum Pathol 2007; 38:741-746.
21. van den Bosch S, Alfred Witjes J. Long-term cancer-specific survival in patients with high-risk, nonmuscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol 2011; 60:493-500.
22. Schrier BP, Hollander MP, Van Rhijn BW, et al. Prognosis of muscleinvasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 2004; 45:292-296.
23. Badalato GM, Gaya JM, Hruby G, et al. Immediate radical cystectomy vs conservative management for high grade cT1 bladder cancer: is there a survival difference? BJU Int 2012; 110:1471-1477.
24. Hautmann RE, Volkmer BG, Gust K. Quantification of the survival benefit of early versus deferred cystectomy in high-risk nonmuscle invasive bladder cancer (T1 G3). World J Urol 2009; 27:347-351.
25. Canter D, Egleston B, Wong YN, et al. Use of radical cystectomy as initial therapy for the treatment of high-grade T1 urothelial carcinoma of the bladder: a SEER database analysis. Urol Oncol 2013; 31:866-870.
26. Cheng L, Pan CX, Yang XJ, et al. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer 2004; 101:957-962.
27. Lynch SP, Shen Y, Kamat A, et al. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol 2013; 64:307-313.
28. Abdollah F, Sun M, Jeldres C, et al. Survival after radical cystectomy of nonbilharzial squamous cell carcinoma vs urothelial carcinoma: a competing-risks analysis. BJU Int 2012; 109:564-569.
29. Scosyrev E, Yao J, Messing E. Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment? Urology 2009; 73:822-827.
30. El-Sebaie M, Zaghloul MS, Howard G, Mokhtar A. Squamous cell carcinoma of the bilharzial and nonbilharzial urinary bladder: a review of etiological features, natural history, and management. Int J Clin Oncol 2005; 10:20-25.
31. Zaghloul MS, Nouh A, Nazmy M, et al. Long-term results of primary adenocarcinoma of the urinary bladder: a report on 192 patients. Urol Oncol 2006; 24:13-20.
32. Wright JL, Porter MP, Li CI, et al. Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder. Cancer 2006; 107:721-728.
33. Wang J, Wang FW, Lagrange CA, et al. Clinical features of sarcomatoid carcinoma (carcinosarcoma) of the urinary bladder: analysis of 221 cases. Sarcoma 2010; 2010:1-7.
34. Dayyani F, Czerniak BA, Sircar K, et al. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol 2013; 189:1656-1661.
35. Massimiliano SGD, Bochner B. Clinical outcomes in patients with T1 micropapillary urothelial carcinoma of the bladder [abstract 1770]. In: American Urological Association Annual Meeting; San Diego; 2013.
36. Ehdaie B, Maschino A, Shariat SF, et al. Comparative outcomes of pure squamous cell carcinoma and urothelial carcinoma with squamous differentiation in patients treated with radical cystectomy. J Urol 2012; 187:74-79.
37. Antunes AA, Nesrallah LJ, Dall'Oglio MF, et al. The role of squamous differentiation in patients with transitional cell carcinoma of the bladder treated with radical cystectomy. Int Braz J Urol 2007; 33:339-345.
38. Mitra AP, Bartsch CC, Bartsch G Jr., et al. Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis. Urol Oncol 2014; 32:117-127.
39. Linder BJ, Frank I, Cheville JC, et al. Outcomes following radical cystectomy for nested variant of urothelial carcinoma: a matched cohort analysis. J Urol 2013; 189:1670-1675.
40. Miller JS, Epstein JI. Noninvasive urothelial carcinoma of the bladder with glandular differentiation: report of 24 cases. Am J Surg Pathol 2009; 33:1241-1248.
41. Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014; 25:152-165.
42. Weinstein JN, Akbani R, Broom BM, et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014; 507:315-322.